在肝癌中识别与代谢相关的基因,通过加权基因共同表达网络分析和机器学习
Taorui Wang1, Zijun Lai2, Shengjun Tang2
1Faculty of Medicine, Macau University of Science and Technology, Taipa, China.
Frontiers in genetics
|October 10, 2025
概括
这项研究确定了六种与代谢相关的基因 (ACADS,ALDH8A1,COX4I2,CYP2C8,DBH,NDST3) 作为肝癌预后的潜在生物标志物. 这些基因也可能作为肝癌治疗的治疗点.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 生物信息学是一种生物信息学.
背景情况:
- 肝癌是癌症死亡的主要原因,通常与代谢失调有关.
- 确定可靠的预后生物标志物和治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 为了确定与肝癌预后相关的代谢相关基因.
- 基于这些生物标志物,发现肝癌的潜在治疗点.
主要方法:
- 使用EdgeR和权重基因联合表达网络分析 (WGCNA) 的转录组数据分析.
- 机器学习算法 (随机森林,支持矢量机器,LASSO) 用于标记基因选择.
- 基因组丰富分析 (GSEA),单样GSEA (ssGSEA) 和RT-PCR用于验证和途径分析.
- 使用DGIdb数据库进行药物发现.
主要成果:
- 确定了234个与代谢相关的基因;使用机器学习选择了7个标记基因.
- 六个基因 (ACADS,ALDH8A1,COX4I2,CYP2C8,DBH,NDST3) 与肝癌患者的生存率和免疫细胞透相关.
- 基因表达模式在独立数据集 (GSE54236) 和临床样本中得到验证.
- 确定了针对这些生物标志物的候选药物,包括PAZOPANIB和ETOPOSIDE.
结论:
- 与新陈代谢相关的基因ACADS,ALDH8A1,COX4I2,CYP2C8,DBH和NDST3显示出作为肝癌预后生物标志物的巨大潜力.
- 这些已识别的基因代表了未来肝癌治疗的有希望的治疗点.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...